AU625856B2
(en)
*
|
1987-07-15 |
1992-07-16 |
United States of America, as represented by the Secretary, U.S. Department of Commerce, The |
Second generation monoclonal antibodies having binding specificity to tag-72 and human carcinomas and methods for employing the same
|
GB8720833D0
(en)
*
|
1987-09-04 |
1987-10-14 |
Celltech Ltd |
Recombinant dna product
|
WO1989007142A1
(en)
*
|
1988-02-05 |
1989-08-10 |
Morrison Sherie L |
Domain-modified constant region antibodies
|
AU4429989A
(en)
*
|
1988-10-19 |
1990-05-14 |
Dow Chemical Company, The |
A novel family of high affinity, modified antibodies for cancer treatment
|
US5162218A
(en)
*
|
1988-11-18 |
1992-11-10 |
The Regents Of The University Of California |
Conjugated polypeptides and methods for their preparation
|
US5215889A
(en)
*
|
1988-11-18 |
1993-06-01 |
The Regents Of The University Of California |
Catalytic and reactive polypeptides and methods for their preparation and use
|
US5530101A
(en)
*
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
IL162181A
(en)
*
|
1988-12-28 |
2006-04-10 |
Pdl Biopharma Inc |
A method of producing humanized immunoglubulin, and polynucleotides encoding the same
|
GB8903022D0
(en)
*
|
1989-02-10 |
1989-03-30 |
Celltech Ltd |
Chemical compounds
|
US5354554A
(en)
*
|
1989-02-10 |
1994-10-11 |
Celltech Limited |
Crosslinked antibodies and processes for their preparation
|
GB8903021D0
(en)
*
|
1989-02-10 |
1989-03-30 |
Celltech Ltd |
Chemical compounds
|
US5714149A
(en)
*
|
1989-02-10 |
1998-02-03 |
Celltech Therapeutics Limited |
Crosslinked antibodies and processes for their preparation
|
GB8905669D0
(en)
*
|
1989-03-13 |
1989-04-26 |
Celltech Ltd |
Modified antibodies
|
CA2018248A1
(en)
*
|
1989-06-07 |
1990-12-07 |
Clyde W. Shearman |
Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
|
GB8916400D0
(en)
*
|
1989-07-18 |
1989-09-06 |
Dynal As |
Modified igg3
|
US5859205A
(en)
*
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
EP0438310A1
(de)
*
|
1990-01-19 |
1991-07-24 |
Merck & Co. Inc. |
Verfahren zur Herstellung von rekombinanten Immunoglobulinen
|
US5185433A
(en)
*
|
1990-04-09 |
1993-02-09 |
Centocor, Inc. |
Cross-linking protein compositions having two or more identical binding sites
|
US5976531A
(en)
*
|
1990-04-19 |
1999-11-02 |
The Dow Chemical Company |
Composite antibodies of human subgroup IV light chain capable of binding to tag-72
|
US6495137B1
(en)
|
1990-04-19 |
2002-12-17 |
The Dow Chemical Company |
Humanized anti-tag-72 monoclonal antibodies using human subgroup 4 kappa light chains
|
GB9009549D0
(en)
*
|
1990-04-27 |
1990-06-20 |
Celltech Ltd |
Recombinant antibody and method
|
GB9009548D0
(en)
*
|
1990-04-27 |
1990-06-20 |
Celltech Ltd |
Chimeric antibody and method
|
GB9014932D0
(en)
*
|
1990-07-05 |
1990-08-22 |
Celltech Ltd |
Recombinant dna product and method
|
GB2276169A
(en)
*
|
1990-07-05 |
1994-09-21 |
Celltech Ltd |
Antibodies specific for carcinoembryonic antigen
|
GB9022543D0
(en)
*
|
1990-10-17 |
1990-11-28 |
Wellcome Found |
Antibody production
|
US5958413A
(en)
*
|
1990-11-01 |
1999-09-28 |
Celltech Limited |
Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor
|
WO1994004679A1
(en)
*
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
US6800738B1
(en)
|
1991-06-14 |
2004-10-05 |
Genentech, Inc. |
Method for making humanized antibodies
|
DE69233254T2
(de)
|
1991-06-14 |
2004-09-16 |
Genentech, Inc., South San Francisco |
Humanisierter Heregulin Antikörper
|
AU654563B2
(en)
*
|
1991-07-24 |
1994-11-10 |
Imperial Chemical Industries Plc |
Proteins
|
JP3951062B2
(ja)
|
1991-09-19 |
2007-08-01 |
ジェネンテック・インコーポレーテッド |
少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、2官能性F(ab’)2抗体の産生のための使用
|
US5869619A
(en)
*
|
1991-12-13 |
1999-02-09 |
Xoma Corporation |
Modified antibody variable domains
|
DE69233204T2
(de)
*
|
1991-12-13 |
2004-07-15 |
Xoma Corp., Berkeley |
Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
|
EP0618969B1
(de)
*
|
1991-12-13 |
2003-06-25 |
The Dow Chemical Company |
An tag-72 bindende zusammengesetzte antikörper mit der humanen leichten kette der untergruppe-iv
|
US5824307A
(en)
*
|
1991-12-23 |
1998-10-20 |
Medimmune, Inc. |
Human-murine chimeric antibodies against respiratory syncytial virus
|
CZ291039B6
(cs)
|
1992-02-06 |
2002-12-11 |
Schering Corporation |
Monoklonální protilátka, hybridom, polypeptid a způsob jeho přípravy, izolovaná DNA, rekombinantní vektor, hostitelská buňka, humanizovaná protilátka a farmaceutický prostředek
|
US6056957A
(en)
*
|
1994-08-04 |
2000-05-02 |
Schering Corporation |
Humanized monoclonal antibodies against human interleukin-5
|
GB9422383D0
(en)
*
|
1994-11-05 |
1995-01-04 |
Wellcome Found |
Antibodies
|
US5811524A
(en)
*
|
1995-06-07 |
1998-09-22 |
Idec Pharmaceuticals Corporation |
Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
|
US20040185039A1
(en)
*
|
2002-08-30 |
2004-09-23 |
Heinz Kohler |
Therapeutic applications of noncovalent dimerizing antibodies
|
US20050033033A1
(en)
*
|
1998-05-04 |
2005-02-10 |
Heinz Kohler |
Trans-membrane-antibody induced inhibition of apoptosis
|
US7569674B2
(en)
*
|
1998-05-04 |
2009-08-04 |
Innexus Biotechnology International Limited |
Autophilic antibodies
|
US6365124B1
(en)
*
|
1998-02-06 |
2002-04-02 |
Biocrystal, Ltd. |
Compositions for detecting and surgically removing lymphoid tissue involved in tumor progression
|
US20090208418A1
(en)
*
|
2005-04-29 |
2009-08-20 |
Innexus Biotechnology Internaltional Ltd. |
Superantibody synthesis and use in detection, prevention and treatment of disease
|
GB9812545D0
(en)
|
1998-06-10 |
1998-08-05 |
Celltech Therapeutics Ltd |
Biological products
|
US6818749B1
(en)
|
1998-10-31 |
2004-11-16 |
The United States Of America As Represented By The Department Of Health And Human Services |
Variants of humanized anti carcinoma monoclonal antibody cc49
|
AU2001240020B9
(en)
*
|
2000-03-01 |
2008-12-04 |
Medimmune, Llc |
High potency recombinant antibodies and method for producing them
|
DK1265928T3
(da)
*
|
2000-01-27 |
2010-11-15 |
Medimmune Llc |
RSV-neutraliserende antistoffer med ultra høj affinitet
|
WO2001061351A1
(fr)
*
|
2000-02-17 |
2001-08-23 |
Laboratory Of Molecular Biophotonics |
Detection d'antigene par voie quantitative
|
DK1283214T3
(da)
|
2000-04-21 |
2007-06-11 |
Fuso Pharmaceutical Ind |
Hidtil ukendte kollektiner
|
US7179900B2
(en)
*
|
2000-11-28 |
2007-02-20 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
US6855493B2
(en)
|
2000-11-28 |
2005-02-15 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
US7482435B2
(en)
|
2000-12-05 |
2009-01-27 |
Alexion Pharmaceuticals, Inc. |
Rationally designed antibodies
|
US20040253242A1
(en)
*
|
2000-12-05 |
2004-12-16 |
Bowdish Katherine S. |
Rationally designed antibodies
|
US7396917B2
(en)
|
2000-12-05 |
2008-07-08 |
Alexion Pharmaceuticals, Inc. |
Rationally designed antibodies
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
AU2002327164A1
(en)
|
2001-01-29 |
2002-12-09 |
Idec Pharmaceuticals Corporation |
Engineered tetravalent antibodies and methods of use
|
AU2002251913A1
(en)
*
|
2001-02-02 |
2002-08-19 |
Millennium Pharmaceuticals, Inc. |
Hybrid antibodies and uses thereof
|
CA2440221C
(en)
*
|
2001-03-07 |
2013-02-05 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Expression technology for proteins containing a hybrid isotype antibody moiety
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
AU2003248744C1
(en)
|
2002-06-28 |
2009-12-24 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Humanized anti-TAG-72 CC49 for diagnosis and therapy of human tumors
|
US7608429B2
(en)
|
2002-10-31 |
2009-10-27 |
Genentech, Inc. |
Methods and compositions for increasing antibody production
|
GB0309126D0
(en)
|
2003-04-17 |
2003-05-28 |
Neutec Pharma Plc |
Clostridium difficile focussed antibodies
|
JP5416338B2
(ja)
*
|
2003-05-09 |
2014-02-12 |
デューク ユニバーシティ |
Cd20特異的抗体およびその使用方法
|
NZ544923A
(en)
*
|
2003-06-27 |
2009-02-28 |
Biogen Idec Inc |
Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous anti-body solutions
|
AU2004255216B2
(en)
|
2003-07-01 |
2010-08-19 |
Immunomedics, Inc. |
Multivalent carriers of bi-specific antibodies
|
GB0315450D0
(en)
*
|
2003-07-01 |
2003-08-06 |
Celltech R&D Ltd |
Biological products
|
HUE026278T2
(en)
|
2003-07-01 |
2016-05-30 |
Ucb Biopharma Sprl |
Modified Fab antibody fragments
|
GB0315457D0
(en)
*
|
2003-07-01 |
2003-08-06 |
Celltech R&D Ltd |
Biological products
|
WO2005014618A2
(en)
*
|
2003-08-08 |
2005-02-17 |
Immunomedics, Inc. |
Bispecific antibodies for inducing apoptosis of tumor and diseased cells
|
US7589181B2
(en)
|
2003-08-29 |
2009-09-15 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Minimally immunogenic variants of SDR-grafted humanized antibody CC49 and their use
|
GB0325836D0
(en)
*
|
2003-11-05 |
2003-12-10 |
Celltech R&D Ltd |
Biological products
|
HUE026260T2
(en)
|
2003-11-21 |
2016-06-28 |
Ucb Biopharma Sprl |
A method for treating multiple sclerosis by inhibiting IL-17 activity
|
GB0329825D0
(en)
*
|
2003-12-23 |
2004-01-28 |
Celltech R&D Ltd |
Biological products
|
ES2442386T3
(es)
|
2004-04-23 |
2014-02-11 |
Bundesrepublik Deutschland Letztvertreten Durch Das Robert Koch-Institut Vertreten Durch Seinen Pr |
Método para el tratamiento de condiciones mediadas por células T por la disminución de las células positivas de ICOS in vivo.
|
US20100111856A1
(en)
*
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
EP3088004B1
(de)
*
|
2004-09-23 |
2018-03-28 |
Genentech, Inc. |
Cystein-manipulierte antikörper und konjugate
|
EP1812068A4
(de)
*
|
2004-10-29 |
2010-06-09 |
Medimmune Inc |
Verfahren zur prävention und behandlung von rsv-infektionen und verwandten leiden
|
WO2006074399A2
(en)
*
|
2005-01-05 |
2006-07-13 |
Biogen Idec Ma Inc. |
Multispecific binding molecules comprising connecting peptides
|
EP3332808B1
(de)
|
2005-03-03 |
2020-09-09 |
Immunomedics Inc. |
Humanisierte l243-antikörper
|
US20100104564A1
(en)
*
|
2005-03-29 |
2010-04-29 |
Genevieve Hansen |
Altered Antibody Fc Regions and Uses Thereof
|
USRE47223E1
(en)
|
2005-06-20 |
2019-02-05 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
GB0514779D0
(en)
*
|
2005-07-19 |
2005-08-24 |
Celltech R&D Ltd |
Biological products
|
SI2298815T1
(sl)
|
2005-07-25 |
2015-08-31 |
Emergent Product Development Seattle, Llc |
Zmanjšanje števila celic b z uporabo molekul, ki se specifično vežejo na cd37 in cd20
|
AU2006290567A1
(en)
*
|
2005-09-14 |
2007-03-22 |
Ucb Pharma S.A |
Comb polymers
|
JP5183484B2
(ja)
|
2005-12-09 |
2013-04-17 |
ユセベ ファルマ ソシエテ アノニム |
ヒトil−6に対して特異性を有する抗体分子
|
MX2008009792A
(es)
*
|
2006-02-01 |
2008-09-01 |
Arana Therapeutics Ltd |
Construccion de anticuerpo de dominio.
|
CA3149553C
(en)
|
2006-06-12 |
2023-11-21 |
Aptevo Research And Development Llc |
Single-chain multivalent binding proteins with effector function
|
GB0614780D0
(en)
|
2006-07-25 |
2006-09-06 |
Ucb Sa |
Biological products
|
GB0619291D0
(en)
|
2006-09-29 |
2006-11-08 |
Ucb Sa |
Altered antibodies
|
GB0620729D0
(en)
|
2006-10-18 |
2006-11-29 |
Ucb Sa |
Biological products
|
EP2609932B1
(de)
|
2006-12-01 |
2022-02-02 |
Seagen Inc. |
Veränderliche target-bindemittel und verwendungen davon
|
CN103214577B
(zh)
|
2007-03-22 |
2015-09-02 |
生物基因Ma公司 |
特异性结合cd154的包括抗体、抗体衍生物和抗体片段在内的结合蛋白及其用途
|
WO2008141044A2
(en)
|
2007-05-08 |
2008-11-20 |
Genentech, Inc. |
Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
|
EP1997830A1
(de)
*
|
2007-06-01 |
2008-12-03 |
AIMM Therapeutics B.V. |
RSV-spezifische Bindemoleküle und Mittel zu ihrer Herstellung
|
BRPI0812465A2
(pt)
*
|
2007-06-08 |
2014-12-02 |
Dow Global Technologies Inc |
Expressão de fragmento de anticorpo solúvel por truncação de domínio ch1
|
WO2009026274A1
(en)
|
2007-08-22 |
2009-02-26 |
Medarex, Inc. |
Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
|
GB0717337D0
(en)
|
2007-09-06 |
2007-10-17 |
Ucb Pharma Sa |
Method of treatment
|
MX2010003718A
(es)
|
2007-10-19 |
2010-04-21 |
Genentech Inc |
Anticuerpos anti-tenb2 producidos por ingenieria de cisteina y conjugados de farmaco y anticuerpo.
|
CN101925364B
(zh)
|
2007-11-27 |
2014-04-30 |
不列颠哥伦比亚大学 |
用于预防和治疗关节炎的14-3-3拮抗剂
|
JP5781765B2
(ja)
|
2007-11-30 |
2015-09-24 |
カロバイオス ファーマシューティカルズ インコーポレイティッド |
シュードモナス・エルギノーサ(PseudomonasAeruginosa)のPcrV抗原に対する抗体
|
ES2613963T3
(es)
*
|
2008-01-18 |
2017-05-29 |
Medimmune, Llc |
Anticuerpos manipulados con cisteína para conjugación específica de sitio
|
WO2009120905A2
(en)
|
2008-03-26 |
2009-10-01 |
Cellerant Therapeutics, Inc. |
Immunoglobulin and/or toll-like receptor proteins associated with myelogenous haematological proliferative disorders and uses thereof
|
MX340204B
(es)
|
2008-04-11 |
2016-06-30 |
Emergent Product Dev Seattle |
Inmunoterapeutico de cd37 y combinacion con quimioterapeutico bifuncional del mismo.
|
GB0807413D0
(en)
|
2008-04-23 |
2008-05-28 |
Ucb Pharma Sa |
Biological products
|
PE20120211A1
(es)
*
|
2009-02-17 |
2012-03-24 |
Ucb Pharma Sa |
Anticuerpos que tienen especificidad por ox40 humana
|
GB0904214D0
(en)
|
2009-03-11 |
2009-04-22 |
Ucb Pharma Sa |
Biological products
|
WO2010121140A1
(en)
|
2009-04-16 |
2010-10-21 |
Facet Biotech Corporation |
ANTI-TNF-α ANTIBODIES AND THEIR USES
|
KR20120034739A
(ko)
|
2009-06-17 |
2012-04-12 |
애보트 바이오테라퓨틱스 코포레이션 |
항-vegf 항체 및 그의 용도
|
US20120283415A1
(en)
|
2009-09-10 |
2012-11-08 |
Ucb Pharma S.A. |
Multivalent Antibodies
|
GB0916630D0
(en)
|
2009-09-22 |
2009-11-04 |
Secr Defence |
Antibody
|
US8568726B2
(en)
|
2009-10-06 |
2013-10-29 |
Medimmune Limited |
RSV specific binding molecule
|
GEP201706604B
(en)
|
2009-10-16 |
2017-01-25 |
Inst Nat De La Santé Et De La Recherché Médicale (Inserm) |
Monoclonal antibodies to progastrin and their uses
|
GB0922434D0
(en)
|
2009-12-22 |
2010-02-03 |
Ucb Pharma Sa |
antibodies and fragments thereof
|
GB0922435D0
(en)
|
2009-12-22 |
2010-02-03 |
Ucb Pharma Sa |
Method
|
WO2011051350A1
(en)
|
2009-10-27 |
2011-05-05 |
Ucb Pharma S.A. |
Function modifying nav 1.7 antibodies
|
US9234037B2
(en)
|
2009-10-27 |
2016-01-12 |
Ucb Biopharma Sprl |
Method to generate antibodies to ion channels
|
ES2639056T3
(es)
|
2009-10-28 |
2017-10-25 |
Abbvie Biotherapeutics Inc. |
Anticuerpos anti-EGFR y sus usos
|
GB0920127D0
(en)
|
2009-11-17 |
2009-12-30 |
Ucb Pharma Sa |
Antibodies
|
GB0920324D0
(en)
|
2009-11-19 |
2010-01-06 |
Ucb Pharma Sa |
Antibodies
|
ES2594893T3
(es)
|
2009-12-16 |
2016-12-23 |
Abbvie Biotherapeutics Inc. |
Anticuerpos anti HER2 y sus usos
|
GB201000467D0
(en)
|
2010-01-12 |
2010-02-24 |
Ucb Pharma Sa |
Antibodies
|
US8993731B2
(en)
|
2010-03-11 |
2015-03-31 |
Ucb Biopharma Sprl |
PD-1 antibody
|
TW201134488A
(en)
*
|
2010-03-11 |
2011-10-16 |
Ucb Pharma Sa |
PD-1 antibodies
|
EP2545073B1
(de)
|
2010-03-12 |
2015-09-30 |
AbbVie Biotherapeutics Inc. |
Ctla4-proteine und ihre verwendungen
|
US10472426B2
(en)
|
2010-03-25 |
2019-11-12 |
Ucb Biopharma Sprl |
Disulfide stabilized DVD-Ig molecules
|
GB201005064D0
(en)
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
JP2013534520A
(ja)
|
2010-06-08 |
2013-09-05 |
ジェネンテック, インコーポレイテッド |
システイン操作抗体及びコンジュゲート
|
GB201014033D0
(en)
|
2010-08-20 |
2010-10-06 |
Ucb Pharma Sa |
Biological products
|
SG10201510762YA
(en)
|
2011-01-14 |
2016-01-28 |
Ucb Pharma Sa |
Antibody molecules which bind il-17a and il-17f
|
EP3617227A3
(de)
|
2011-09-16 |
2020-06-03 |
UCB Biopharma SRL |
Neutralisierende antikörpern gegen das haupt exotoxin tcda von clostridium difficile
|
UA112203C2
(uk)
|
2011-11-11 |
2016-08-10 |
Юсб Фарма С.А. |
Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
|
CA2887880A1
(en)
|
2011-11-23 |
2013-05-30 |
The Board Of Regents Of The University Of Texas System |
Proteomic identification of antibodies
|
GB201203051D0
(en)
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
GB201203071D0
(en)
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
GB201208370D0
(en)
|
2012-05-14 |
2012-06-27 |
Ucb Pharma Sa |
Antibodies
|
US20140154255A1
(en)
|
2012-11-30 |
2014-06-05 |
Abbvie Biotherapeutics Inc. |
Anti-vegf antibodies and their uses
|
GB201223276D0
(en)
|
2012-12-21 |
2013-02-06 |
Ucb Pharma Sa |
Antibodies and methods of producing same
|
PT2953976T
(pt)
*
|
2013-02-08 |
2021-06-23 |
Novartis Ag |
Sítios específicos de modificação de anticorpos para preparar imunoconjugados
|
AU2014233503A1
(en)
|
2013-03-15 |
2015-09-24 |
Abbvie Biotechnology Ltd. |
Anti-CD25 antibodies and their uses
|
AU2014233528B2
(en)
|
2013-03-15 |
2019-02-28 |
Abbvie Biotherapeutics Inc. |
Fc variants
|
WO2014145000A2
(en)
|
2013-03-15 |
2014-09-18 |
Abbvie Biotherapeutics Inc. |
Anti-cd25 antibodies and their uses
|
GB201315487D0
(en)
|
2013-08-30 |
2013-10-16 |
Ucb Pharma Sa |
Antibodies
|
WO2015035044A2
(en)
|
2013-09-04 |
2015-03-12 |
Abbvie Biotherapeutics Inc. |
Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
|
GB201320066D0
(en)
|
2013-11-13 |
2013-12-25 |
Ucb Pharma Sa |
Biological products
|
US8992927B1
(en)
|
2014-07-15 |
2015-03-31 |
Kymab Limited |
Targeting human NAV1.7 variants for treatment of pain
|
US9067998B1
(en)
|
2014-07-15 |
2015-06-30 |
Kymab Limited |
Targeting PD-1 variants for treatment of cancer
|
US9914769B2
(en)
|
2014-07-15 |
2018-03-13 |
Kymab Limited |
Precision medicine for cholesterol treatment
|
US8986694B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Targeting human nav1.7 variants for treatment of pain
|
US9045545B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision medicine by targeting PD-L1 variants for treatment of cancer
|
MX2016009347A
(es)
|
2014-01-20 |
2017-02-02 |
Ucb Biopharma Sprl |
Proceso para la reconstitucion de una forma solida de una composicion farmaceutica.
|
EP4190809A1
(de)
|
2014-02-11 |
2023-06-07 |
Seagen Inc. |
Selektive reduktion von proteinen
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
EP2944962A1
(de)
|
2014-05-14 |
2015-11-18 |
UCB Biopharma SPRL |
Verfahren zur Bestimmung von Antikörperspezifität
|
GB201411320D0
(en)
|
2014-06-25 |
2014-08-06 |
Ucb Biopharma Sprl |
Antibody construct
|
US9139648B1
(en)
|
2014-07-15 |
2015-09-22 |
Kymab Limited |
Precision medicine by targeting human NAV1.9 variants for treatment of pain
|
AR101844A1
(es)
|
2014-09-12 |
2017-01-18 |
Genentech Inc |
Anticuerpos y conjugados modificados genéticamente con cisteína
|
US10035823B2
(en)
|
2014-09-29 |
2018-07-31 |
The Regents Of The University Of California |
Compositions for expanding regulatory T cells (TREG), and treating autoimmune and inflammatory diseases and conditions
|
CN107250157B
(zh)
|
2014-11-21 |
2021-06-29 |
百时美施贵宝公司 |
包含修饰的重链恒定区的抗体
|
CN113773388A
(zh)
|
2014-11-21 |
2021-12-10 |
百时美施贵宝公司 |
抗cd73抗体及其用途
|
CA2969889A1
(en)
|
2014-12-22 |
2016-06-30 |
Ucb Biopharma Sprl |
Protein manufacture
|
JP2018510212A
(ja)
|
2015-03-06 |
2018-04-12 |
ツェー・エス・エル・ベーリング・レコンビナント・ファシリティ・アクチエンゲゼルシャフト |
向上した半減期を有する改変したフォンヴィレブランド因子
|
GB201506869D0
(en)
|
2015-04-22 |
2015-06-03 |
Ucb Biopharma Sprl |
Method
|
GB201506870D0
(en)
|
2015-04-22 |
2015-06-03 |
Ucb Biopharma Sprl |
Method
|
JP2018515082A
(ja)
|
2015-04-30 |
2018-06-14 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
代謝障害を処置するための抗ap2抗体及び抗原結合剤
|
GB201508180D0
(en)
|
2015-05-13 |
2015-06-24 |
Ucb Biopharma Sprl |
Antibodies
|
MY195000A
(en)
|
2015-05-27 |
2022-12-30 |
Ucb Biopharma Sprl |
Method for the treatment of neurological disease
|
MA42377A
(fr)
|
2015-07-06 |
2018-05-16 |
Ucb Biopharma Sprl |
Anticorps se liant à tau
|
AU2016304764C1
(en)
*
|
2015-08-07 |
2023-06-01 |
Imaginab, Inc. |
Antigen binding constructs to target molecules
|
US10906990B2
(en)
|
2015-08-19 |
2021-02-02 |
Riken |
Antibody with non-natural amino acid introduced therein
|
WO2017053469A2
(en)
|
2015-09-21 |
2017-03-30 |
Aptevo Research And Development Llc |
Cd3 binding polypeptides
|
BR112018008075A2
(pt)
|
2015-10-27 |
2018-12-04 |
Ucb Biopharma Sprl |
métodos de tratamento usando anticorpos anti-il-17a/f
|
WO2017096361A1
(en)
|
2015-12-04 |
2017-06-08 |
Merrimack Pharmaceuticals, Inc. |
Disulfide-stabilized fabs
|
GB201522394D0
(en)
|
2015-12-18 |
2016-02-03 |
Ucb Biopharma Sprl |
Antibodies
|
EP3184544A1
(de)
|
2015-12-23 |
2017-06-28 |
Julius-Maximilians-Universität Würzburg |
Glycoprotein-v-inhibitoren zur verwendung als koagulansien
|
GB201602414D0
(en)
|
2016-02-10 |
2016-03-23 |
Nascient Ltd |
Biological materials and uses thereof
|
MA43716A
(fr)
|
2016-03-17 |
2018-11-28 |
Numab Innovation Ag |
Anticorps anti-tnf et fragments fonctionnels de ceux-ci
|
CN109153718B
(zh)
|
2016-03-17 |
2022-02-08 |
努玛治疗有限公司 |
抗TNFα抗体及其功能片段
|
ES2836349T3
(es)
|
2016-03-17 |
2021-06-24 |
Tillotts Pharma Ag |
Anticuerpos anti-TNF-alfa y fragmentos funcionales de los mismos
|
DK3219727T3
(da)
|
2016-03-17 |
2021-01-04 |
Tillotts Pharma Ag |
Anti-THF-alpha-antistoffer og funktionelle fragmenter deraf
|
JP7049311B2
(ja)
|
2016-03-17 |
2022-04-06 |
ヌマブ イノヴェイション アーゲー |
抗TNFα抗体およびそれらの機能的断片
|
GB201610198D0
(en)
|
2016-06-10 |
2016-07-27 |
Ucb Biopharma Sprl |
Anti-ige antibodies
|
CN109923129A
(zh)
|
2016-08-26 |
2019-06-21 |
新加坡科技研究局 |
巨噬细胞刺激蛋白受体(或RON-Recepteur d,Origine Nantais)抗体及其用途
|
GB201616596D0
(en)
|
2016-09-29 |
2016-11-16 |
Nascient Limited |
Epitope and antibodies
|
US11779604B2
(en)
|
2016-11-03 |
2023-10-10 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses and methods
|
GB201621635D0
(en)
|
2016-12-19 |
2017-02-01 |
Ucb Biopharma Sprl |
Crystal structure
|
US11266745B2
(en)
|
2017-02-08 |
2022-03-08 |
Imaginab, Inc. |
Extension sequences for diabodies
|
JP7337698B2
(ja)
|
2017-02-28 |
2023-09-04 |
シージェン インコーポレイテッド |
コンジュゲート化のためのシステイン突然変異抗体
|
US20200165347A1
(en)
|
2017-06-30 |
2020-05-28 |
Aslan Pharmaceuticals Pte Ltd |
Method of treatment using il-13r antibody
|
CA3084687C
(en)
|
2017-12-05 |
2024-01-02 |
Progastrine Et Cancers S.A R.L. |
Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
|
GB201802486D0
(en)
|
2018-02-15 |
2018-04-04 |
Ucb Biopharma Sprl |
Methods
|
CA3092414A1
(en)
|
2018-02-27 |
2019-09-06 |
Ecs-Progastrin Sa |
Progastrin as a biomarker for immunotherapy
|
GB201811368D0
(en)
|
2018-07-11 |
2018-08-29 |
Ucb Biopharma Sprl |
Antibody
|
KR20210078517A
(ko)
|
2018-10-16 |
2021-06-28 |
유씨비 바이오파마 에스알엘 |
중증근무력증의 치료 방법
|
US20210277131A1
(en)
|
2019-03-26 |
2021-09-09 |
Aslan Pharmaceuticals Pte Ltd |
TREATMENT EMPLOYING ANTI-IL-l3R ANTIBODY OR BINDING FRAGMENT THEREOF
|
CN114641501A
(zh)
|
2019-09-04 |
2022-06-17 |
Y生物股份有限公司 |
抗vsig4抗体或抗原结合片段及其用途
|
GB201919062D0
(en)
|
2019-12-20 |
2020-02-05 |
Ucb Biopharma Sprl |
Antibody
|
GB201919058D0
(en)
|
2019-12-20 |
2020-02-05 |
Ucb Biopharma Sprl |
Multi-specific antibodies
|
GB201919061D0
(en)
|
2019-12-20 |
2020-02-05 |
Ucb Biopharma Sprl |
Multi-specific antibody
|
GB202001447D0
(en)
|
2020-02-03 |
2020-03-18 |
Ucb Biopharma Sprl |
Antibodies
|
CA3200836A1
(en)
|
2020-12-07 |
2022-06-16 |
UCB Biopharma SRL |
Antibodies against interleukin-22
|
JP2023551981A
(ja)
|
2020-12-07 |
2023-12-13 |
ユーシービー バイオファルマ エスアールエル |
多重特異性抗体及び抗体の組み合わせ
|
WO2022186773A1
(en)
|
2021-03-01 |
2022-09-09 |
Aslan Pharmaceuticals Pte Ltd |
TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF IN AN ALLERGIC POPULATION
|
WO2022186772A1
(en)
|
2021-03-01 |
2022-09-09 |
Aslan Pharmaceuticals Pte Ltd |
TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF
|
TW202302645A
(zh)
|
2021-03-03 |
2023-01-16 |
法商皮爾法伯製藥公司 |
抗vsig4抗體或抗原結合片段及其用途
|
IL308106A
(en)
|
2021-04-30 |
2023-12-01 |
Pf Medicament |
A new antibody against VISTA
|
WO2022233764A1
(en)
|
2021-05-03 |
2022-11-10 |
UCB Biopharma SRL |
Antibodies
|
GB202111905D0
(en)
|
2021-08-19 |
2021-10-06 |
UCB Biopharma SRL |
Antibodies
|
WO2023048650A1
(en)
|
2021-09-27 |
2023-03-30 |
Aslan Pharmaceuticals Pte Ltd |
TREATMENT OF PRURITIS EMPLOYING ANTI-IL13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF
|
WO2023048651A1
(en)
|
2021-09-27 |
2023-03-30 |
Aslan Pharmaceuticals Pte Ltd |
Method for treatment of moderate to severe atoptic dematitis
|
WO2023075702A1
(en)
|
2021-10-29 |
2023-05-04 |
Aslan Pharmaceuticals Pte Ltd |
Anti-il-13r antibody formulation
|
WO2023140780A1
(en)
|
2022-01-24 |
2023-07-27 |
Aslan Pharmaceuticals Pte Ltd. |
Method of treating inflammatory disease
|
TW202337905A
(zh)
|
2022-02-23 |
2023-10-01 |
新加坡商亞獅康私人有限公司 |
抗il13r抗體之糖基化形式
|
WO2024043837A1
(en)
|
2022-08-26 |
2024-02-29 |
Aslan Pharmaceuticals Pte Ltd |
High concentration anti-il13r antibody formulation
|
WO2024054157A1
(en)
|
2022-09-06 |
2024-03-14 |
Aslan Pharmaceuticals Pte Ltd |
Treatment for sleep loss or sleep disturbance in patients with dermatitis
|